Sagimet Biosciences Inc.(SGMT)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $2.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
SGMT Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Sagimet Biosciences Inc. (SGMT), a Healthcare sector company. SGMT is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $2.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Sagimet Biosciences Inc. reports net income of $-10.7M, free cash flow of $-8.6M. Top institutional holders of SGMT by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, Woodline Partners, MARSHALL WACE, LLP, based on the most recent SEC filings. SGMT trades on the Nasdaq exchange and files with the SEC under CIK 1400118. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SGMT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Sagimet Biosciences Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-10.7M
Free Cash Flow
Q1 2026
$-8.6M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
-12.0% YoYOperating Income
-4.5% YoYEPS (Diluted)
-9.0% YoYTotal Assets
-27.3% YoYOp. Cash Flow
-7.6% YoY| Metric | FY 2025 | FY 2024 | FY 2022 |
|---|---|---|---|
| Net Income | $-51.0M -12.0% | $-45.6M -49.4% | $-30.5M |
| Operating Income | $-56.9M -4.5% | $-54.5M -75.3% | $-31.1M |
| EPS (Diluted) | $-1.58 -9.0% | $-1.45 +99.1% | $-165.20 |
| Total Assets | $116.5M -27.3% | $160.3M +385.2% | $33.0M |
| Operating Cash Flow | $-45.6M -7.6% | $-42.4M -73.3% | $-24.5M |
AI Insight: SGMT Financial Trends
Sagimet generates no revenue while equity has eroded from $183M to $102M over eight consecutive quarters of cash burn.
• Equity has declined every single quarter, falling from $183M in Q2 2024 to $102M in Q1 2026 — a $81M reduction.
• Operating losses widened to a peak of $-20M in Q1 2025 before partially moderating to $-11M in Q4 2025 and $-12M in Q1 2026.
• Operating cash outflows have ranged between $-6M and $-20M per quarter with no revenue to offset burn.
⚠ At the Q1 2026 burn rate of ~$9–12M per quarter, remaining equity of $102M implies roughly 8–11 quarters of runway.
⚠ No revenue recorded across all eight quarters; any pipeline milestone or licensing event would be a critical inflection.
AI Insight: SGMT Ratio Trends
Sagimet's returns remain deeply negative across all quarters, with ROIC oscillating between -23% and -57% — no clear path to profitability visible in the data.
• ROIC deteriorated from -23.1% in Q2 2024 to -57.2% in Q1 2025, a 34pp swing, before partially recovering to -45.7% in Q1 2026.
• ROA has remained persistently negative, ranging from -17.2% to -49.7% across all reported quarters with no sustained improvement.
• OpMargin, NPM, and D/E are absent across all periods, severely limiting visibility into cost structure and leverage.
⚠ ROE worsened to -41.6% in Q1 2026 after a partial recovery to -34.4% in Q4 2025 — no durable improvement trend established.
⚠ TTM ROIC of -47.6% confirms sustained capital destruction; any cash runway timeline is unquantifiable without balance sheet data.
Get alerted when SGMT's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Sagimet Biosciences Inc. including:
Top Institutional Holders of SGMT
VANGUARD CAPITAL MANAGEMENT LLC
$5.7M1,098,919 shWoodline Partners LP
$5.2M1,000,943 shMARSHALL WACE, LLP
$5.0M966,253 shBAKER BROS. ADVISORS LP
$5.0M952,996 shAffinity Asset Advisors, LLC
$4.5M868,020 shMILLENNIUM MANAGEMENT LLC
$4.5M862,303 shBlackRock, Inc.
$4.2M799,943 shHillhouse Capital Advisors, Ltd.
$3.8M724,800 shRENAISSANCE TECHNOLOGIES LLC
$3.3M625,469 shD. E. Shaw & Co., Inc.
$2.2M411,570 sh
| Fund | Value | Shares |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $5.7M | 1,098,919 |
| Woodline Partners LP | $5.2M | 1,000,943 |
| MARSHALL WACE, LLP | $5.0M | 966,253 |
| BAKER BROS. ADVISORS LP | $5.0M | 952,996 |
| Affinity Asset Advisors, LLC | $4.5M | 868,020 |
| MILLENNIUM MANAGEMENT LLC | $4.5M | 862,303 |
| BlackRock, Inc. | $4.2M | 799,943 |
| Hillhouse Capital Advisors, Ltd. | $3.8M | 724,800 |
| RENAISSANCE TECHNOLOGIES LLC | $3.3M | 625,469 |
| D. E. Shaw & Co., Inc. | $2.2M | 411,570 |
More Healthcare Companies
View all Healthcare →Put SGMT on your watchlist
Track score changes the day Sagimet Biosciences Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is SGMT a good stock to buy?
13F Pro's AI-powered analysis of Sagimet Biosciences Inc. (SGMT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SGMT are available on the SGMT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own SGMT?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SGMT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Sagimet Biosciences Inc.'s investment landscape.